

## Contents

### Clinical Studies

- 271 The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis**  
Sonehara, K.; Tateishi, K.; Araki, T.; Komatsu, M.; Yamamoto, H.; Koizumi, T.; Hanaoka, M. (Matsumoto)
- 280 Prognostic Factors and Survival Outcomes among Patients with Breast Cancer and Brain Metastases at Diagnosis: A National Cancer Database Analysis**  
Zimmerman, B.S.; Seidman, D.; Cascetta, K.P.; Ru, M.; Moshier, E.; Tiersten, A. (New York, NY)
- 292 Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients**  
Casadei-Gardini, A. (Milan); Filippi, R. (Turin); Rimini, M. (Modena); Rapposelli, I.G. (Meldola); Fornaro, L. (Pisa); Silvestris, N. (Bari); Aldrighetti, L. (Milan); Aimar, G. (Turin/Candiolo); Rovesti, G. (Modena); Bartolini, G. (Meldola); Vivaldi, C. (Pisa); Brunetti, O. (Bari); Sperti, E.; La Face, R. (Turin); Ratti, F. (Milan); Andrikou, K. (Modena); Valgiusti, M. (Meldola); Bernardini, L. (Pisa); Argentiero, A. (Bari); Fenocchio, E. (Candiolo); Frassinetti, G.L. (Meldola); Cesario, S. (Pisa); Giovannelli, F. (Bari); Quarà, V. (Turin/Candiolo); Leone, F. (Ponderano); Cascinu, S. (Milan)
- 300 Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study**  
Pietge, H.; Sánchez-Velázquez, P.; Akhoundova, D.; Siebenhüner, A.; Winder, T.; Bachmann, H.; Nguyen-Kim, T.D.L. (Zurich); Breitenstein, S. (Winterthur); Knuth, A.; Petrowsky, H.; Pestalozzi, B.; Clavien, P. A.; Samaras, P. (Zurich)
- 310 Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma**  
Gottlieb, S.; O'Grady, C.; Glikberg, A.; Kent, P. (Chicago, IL)
- 318 Prediction of Recurrence in Patients with Stage III Colon Cancer Using Conventional Clinicopathological Factors and Peripheral Blood Test Data: A New Analysis with Artificial Intelligence**  
Kamei, Y. (Isehara); Takayama, T. (Hachioji); Suzuki, T. (Isehara); Furihata, K. (Hachioji); Otsuki, M. (Tokyo); Sadahiro, S. (Isehara)
- 327 Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy**  
Amioka, K.; Kawaoka, T.; Ogawa, Y.; Kikukawa, C.; Naruto, K.; Yoshikawa, Y.; Ando, Y.; Kosaka, Y.; Uchikawa, S.; Morio, K.; Fujino, H.; Nakahara, T.; Murakami, E.; Yamauchi, M.; Tsuge, M.; Hiramatsu, A.; Imamura, M.; Fukuhara, T.; Mori, N.; Takaki, S.; Tsuji, K.; Masaki, K.; Honda, Y.; Kouno, H.; Kohno, H. (Hiroshima); Chayama, K. (Hiroshima/Yokohama); Aikata, H. (Hiroshima)

### Clinical Translational Research

- 336 Genetic Polymorphisms in Activating Transcription Factor 3 Binding Site and the Prognosis of Early-Stage Non-Small Cell Lung Cancer**  
Kang, H.-G.; Park, J.E.; Lee, S.Y.; Choi, J.E.; Do, S.K.; Hong, M.J.; Lee, J.H.; Jeong, J.Y.; Do, Y.W.; Lee, E.B.; Shin, K.M.; Lee, W.K.; Choi, S.H.; Lee, Y.H.; Seo, H.w.; Yoo, S.S.; Lee, J.; Cha, S.I.; Kim, C.H. (Daegu); Cho, S.; Jheon, S. (Seoul); Park, J.Y. (Daegu)

### Cover illustration

© S. Karger AG, Basel

**Karger** 

© 2021 S. Karger AG, Basel

Access to full text and tables of contents,  
including tentative ones for forthcoming issues:  
[www.karger.com/ocl](http://www.karger.com/ocl)